Fig. 4

FSTL1 interacts with ZEB1 and enhances EMT. (A–B) Pathway enrichment analysis of FSTL1 knockdown. (C) Western blot of EMT markers after FSTL1 knockdown. (D–E) Co-IP for FSTL1 and ZEB1. (F) Immunofluorescence co-localization of FSTL1 and ZEB1, scale bars 50 μm. (G) Immunocytochemistry of E-cadherin, N-cadherin and Vimentin after FSTL1 knockdown, scale bars 10 μm. (H) qPCR after A431 rt-FSTL1 treatment. (I) Western blot after A431 rt-FSTL1 treatment. Data were presented as the mean ± SD. (ns, non-significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001)